Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 35,550 KRW
Change Today -250.00 / -0.70%
Volume 104.8K
096530 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 12:05 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

seegene inc (096530) Snapshot

Open
35,800
Previous Close
35,800
Day High
36,200
Day Low
35,200
52 Week High
07/28/14 - 42,800
52 Week Low
12/22/14 - 29,350
Market Cap
899.6B
Average Volume 10 Days
393.6K
EPS TTM
384.67
Shares Outstanding
25.3M
EX-Date
--
P/E TM
92.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for SEEGENE INC (096530)

Related News

No related news articles were found.

seegene inc (096530) Related Businessweek News

No Related Businessweek News Found

seegene inc (096530) Details

Seegene, Inc. develops molecular diagnostics systems for various applications. It offers IVD reagets comprising respiratory pathogens for the detection of respiratory viruses and bacteria, pneumonia bacteria, and influenza A and influenza B virus; sexually transmitted infections causative pathogens detection product; human papillomavirus detection products; tuberculosis detection products; Magicplex sepsis real-time test screens; meningitis pathogens for the detection of viruses and bacteria causing human meningitis; and diarrhea pathogens for the detection of viruses and bacteria causing diarrhea. The company also provides Anyplex and Seeplex products for the detection of vanA, vanB, and vanC genes; two mutations causing clarithromycin-resistance; Apolipoprotein E genotypes from blood samples; hepatitis A, B and C virus; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, FNAB, H&E slides, and paraffin-embedded tissues; BCR/ABL fusion gene from blood and whole bone marrow; and CMV infection from whole blood and plasma. In addition, it offers automatic real time detection systems; liquid handling workstations and automated magnetic bead based nucleic acid extractions systems; PCR machines; LabChip, a nucleic acid separations system; and MultiNA, a microchip electrophoresis system. Seegene, Inc. has operations in Asia, Oceania, the Middle East, Africa, the United States, and South Korea, as well as central, northern, eastern, and west Europe. The company was founded in 2000 and is headquartered in Seoul, South Korea.

Founded in 2000

seegene inc (096530) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

seegene inc (096530) Key Developments

Seegene, Inc., Annual General Meeting, Mar 27, 2015

Seegene, Inc., Annual General Meeting, Mar 27, 2015., at 09:00 Korea Standard Time. Location: Taiyuan 65-5 Building (main) Seegene B1 AuditoriumBangi-dong. Agenda: To consider audit report; to consider business report for 15th period ended December 31, 2014; to consider appointment of directors; and to approve director remuneration.

Seegene Inc. Receives Health Canada Approval for New Allplex(TM) Respiratory Molecular Test

Seegene Inc. announced that Health Canada has approved its 6-target Allplex(TM) Respiratory Panel 5 assay, which identify Influenza virus A and B, RSV A and B, and Influenza A virus subtypes H1 and H3. Allplex(TM) tests are based on Seegene's innovative MuDT(TM) technology enabling simultaneous detection and quantification of multiple targets in a single fluorescence channel, without melting curve analysis. This approval further builds on Seegene's strong and growing market presence in the Canadian molecular diagnostics market. Seegene now offers 10 multiplexed infectious disease molecular assays in Canada. With the newly approved Allplex(TM) Respiratory Panel 5 assay, Seegene intends to further penetrate into the respiratory screening market that accounts for more than 70% of the overall Canadian respiratory testing market.

Seegene Receives FDA Clearance for Its Herpes Simplex Virus Molecular Test

Seegene Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for its TOCE based herpes simplex virus (HSV) types 1 and 2 assay. This is the first product that Seegene has taken through the FDA, and it opens the way for Seegene's other planned FDA submissions of multiplex real-time PCR reagents. Allplex tests are based on its breakthrough MuDT technology that allows simultaneous detection and quantification of multiple targets in a single fluorescence channel, without melting curve analysis. Allplex tests are the most comprehensive and cost-effective multiplexed PCR molecular assays for infectious disease in the industry.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
096530:KS 35,550.00 KRW -250.00

096530 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cepheid $56.83 USD +0.73
GenMark Diagnostics Inc $10.11 USD +0.51
Luminex Corp $15.84 USD +0.32
QIAGEN NV €21.08 EUR -0.209
Sequenom Inc $4.59 USD +0.15
View Industry Companies
 

Industry Analysis

096530

Industry Average

Valuation 096530 Industry Range
Price/Earnings 99.5x
Price/Sales 14.1x
Price/Book 9.6x
Price/Cash Flow 67.3x
TEV/Sales 13.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEEGENE INC, please visit www.seegene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.